gsk239512 and Multiple-Sclerosis--Relapsing-Remitting

gsk239512 has been researched along with Multiple-Sclerosis--Relapsing-Remitting* in 1 studies

Trials

1 trial(s) available for gsk239512 and Multiple-Sclerosis--Relapsing-Remitting

Article	Year
Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study. Journal of neurology, 2017, Volume: 264, Issue:2 Topics: Adjuvants, Immunologic; Adult; Benzazepines; Brain; Double-Blind Method; Drug Therapy, Combination; Female; Glatiramer Acetate; Gray Matter; Histamine Antagonists; Humans; Injections, Intramuscular; Interferon beta-1a; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Myelin Sheath; Neuroprotective Agents; Single-Blind Method; White Matter; Young Adult	2017

Article

Year

Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.

Journal of neurology, 2017, Volume: 264, Issue:2

Topics: Adjuvants, Immunologic; Adult; Benzazepines; Brain; Double-Blind Method; Drug Therapy, Combination; Female; Glatiramer Acetate; Gray Matter; Histamine Antagonists; Humans; Injections, Intramuscular; Interferon beta-1a; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Myelin Sheath; Neuroprotective Agents; Single-Blind Method; White Matter; Young Adult

2017